At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections. Data presented at ASH 2025 suggest ...
Key abstracts on multiple myeloma from the 2025 American Society of Hematology Annual Meeting are reported by Dr Joseph Mikhael, chief medical officer of the International Myeloma Foundation. Dr ...
So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...
In the treatment of newly diagnosed multiple myeloma (MM), carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the long-held cornerstone regimen of ...
In vivo CAR T-cell therapies showed promise, with significant developments in partnerships and financing, culminating in a breakthrough for relapsed/refractory multiple myeloma. Precision medicine in ...
Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...
The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results